MAIA Biotechnology, Inc.
MAIA Biotechnology is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Its lead drug candidate, ateganosine, is an investigational telomere-targeting agent being evaluated for non-small cell lung cancer (NSCLC), including in combination with immune checkpoint inhibitors. MAIA is conducting the Phase 2 THIO-101 trial and the Phase 3 THIO-104 trial in NSCLC. It also plans Phase 2 trials of ateganosine in hepatocellular carcinoma, colorectal cancer and small cell lung cancer, and is developing additional telomere-targeting drug candidates. MAIA sponsors and funds its planned trials in those three indications, with BeOne Medicines supplying tislelizumab. The company retains global development and commercial rights to ateganosine. MAIA is headquartered in Chicago, Illinois.
No SEC Form 4 filings for $MAIA in the last 30 days.
See all $MAIA insider activity →MAIA Biotechnology reported a narrower net loss of $7.18M in 3Q 2026, with EPS at ($0.12), compared to ($0.27) a year ago. The company had no revenue but reduced R&D expenses by 16%. THIO-104 trial enrollment reached 65 patients, and THIO-101 U.S. trial expansion began. Spain and Portugal approved patient screening for THIO-104.
MAIA Biotechnology completed enrollment for Part C of its Phase 2 THIO-101 trial and reported 65 patients enrolled in its Phase 3 THIO-104 trial, targeting 100 by 2026. Interim analysis is planned for 2027, according to the company.
MAIA Biotechnology (NYSE American: MAIA) reported milestones in its Phase 2 and Phase 3 trials for ateganosine, a telomere-targeting agent for non-small cell lung cancer (NSCLC). Enrollment is complete for Part C of the Phase 2 trial, with 90.5% interim disease control reported. The Phase 3 trial has reached 65% of its 100-patient enrollment target. The FDA granted Fast Track designation to ateganosine in July 2025.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning MAIA (MAIA Biotechnology, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent MAIA coverage spans financial news, insider activity and earnings.
Loss narrowing and EPS improvement may lift sentiment, but the company still reports no revenue and a loss, limiting upside.
The enrollment milestones indicate continued progress in the NSCLC program, setting up a future data readout that could move the stock.
The enrollment progress signals continued trial momentum and may lift the stock as investors anticipate forthcoming data.
The trial expansion adds new patient enrollment sites, increasing the likelihood of reaching the 100‑patient dosing target by year‑end.
First U.S. patient dosing marks trial progression and may unlock further funding.
AlphAI scores every news story that mentions MAIA with an AI model for sentiment and relevance, and aggregates insider trades from MAIA Biotechnology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
MAIA Biotechnology reported a narrower net loss of $7.18M in 3Q 2026, with EPS at ($0.12), compared to ($0.27) a year ago. The company had no revenue but reduced R&D expenses by 16%. THIO-104 trial enrollment reached 65 patients, and THIO-101 U.S. trial expansion began. Spain and Portugal approved patient screening for THIO-104.
MAIA Biotechnology completed enrollment for Part C of its Phase 2 THIO-101 trial and reported 65 patients enrolled in its Phase 3 THIO-104 trial, targeting 100 by 2026. Interim analysis is planned for 2027, according to the company.
MAIA Biotechnology (NYSE American: MAIA) reported milestones in its Phase 2 and Phase 3 trials for ateganosine, a telomere-targeting agent for non-small cell lung cancer (NSCLC). Enrollment is complete for Part C of the Phase 2 trial, with 90.5% interim disease control reported. The Phase 3 trial has reached 65% of its 100-patient enrollment target. The FDA granted Fast Track designation to ateganosine in July 2025.
MAIA Biotechnology expanded its Phase 3 THIO-104 trial for Ateganosine, an investigational lung cancer treatment, into Spain and Portugal. The study aims to enroll 100 patients by 2026, with an interim analysis planned for 2027. MAIA's stock has traded between $0.87 and $3.19 in the past year, closing at $1.32 on Wednesday.
DataMEDS AI (MEDS) rose 295.53% after acquiring Helomics for $1.5M, expanding into precision oncology. Tempest Therapeutics (TPST) gained 58.86% with a CAR-T licensing deal. NeurAxis (NRXS) increased 22.63% on expanded insurance coverage for its PENFS therapy. MAIA Biotechnology (MAIA) rose 5.22% after dosing the first U.S. patient in its THIO-101 trial.
MAIA Biotechnology, Inc. (NYSE American: MAIA) dosed the first U.S. patient in its Phase 2 THIO-101 trial for ateganosine in third-line non-small cell lung cancer (NSCLC). The trial is funded by a $2.3 million NIH grant. Ateganosine has FDA Fast Track designation and showed promising overall survival data in prior trials.
On September 15, 2026, 162 insider stock purchases were reported. Notable transactions include Cascade Investment buying 176,547 shares of Republic Services (RSG) for $39.4M, Tricor PMT25 Holdings buying 525,000 shares of CPI Card Group (PMTS) for $11.3M, and Devon Energy (DVN) CEO buying 3,913 shares for $199,876.
Vitoc Vlad (Chief Executive Officer) purchased 73,000 shares of MAIA Biotechnology, Inc. (MAIA) at $1.37 ($0.10M total) on 2026-09-14.
Guerrero Ramiro purchased 37,595 shares of MAIA Biotechnology, Inc. (MAIA) at $1.32 on 2026-09-10.
Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.
